Guidelines

Guideline recommends combination therapy for smoking cessation in cancer patients


 

References

The National Comprehensive Cancer Network has published a new guideline on smoking cessation for cancer patients that recommends combining pharmacologic therapy with counseling as the most effective approach, along with rigorous review and close follow-ups to prevent relapses.

“Although the medical community recognizes the importance of smoking cessation, supporting patients in ceasing to smoke is generally not done well. Our hope is that by addressing smoking cessation in a cancer patient population, we can make it easier for oncologists to effectively support their patients in achieving their smoking cessation goals,” Dr. Peter Shields, deputy director of the Ohio State University Comprehensive Cancer Center, said in a written statement. Of the estimated 590,000 cancer deaths in 2015, about 170,000, or nearly 30%, will be caused by tobacco smoking. Quitting tobacco improves cancer treatment effectiveness and reduces cancer recurrence, according to the NCCN.

Read the full statement on the NCCN website.

Recommended Reading

House bill would allow corrective action plan for DEA violators
MDedge Hematology and Oncology
DEA moves hydrocodone combination products to schedule II
MDedge Hematology and Oncology
AHA wants e-cigarettes regulated but notes they help some smokers quit
MDedge Hematology and Oncology
WHO to push for public ban of e-cigarettes
MDedge Hematology and Oncology
Hydrocodone rescheduling takes effect Oct. 6
MDedge Hematology and Oncology
FDA approves new abuse-prevention labeling for extended-release Embeda
MDedge Hematology and Oncology
FDA approves extended-release hydrocodone with abuse-deterrent features
MDedge Hematology and Oncology
Hookah, snus users more likely to start smoking
MDedge Hematology and Oncology
NIH report on long-term opioid treatment cites lack of data, research needs
MDedge Hematology and Oncology
Abuse-deterrent formulation of extended-release hydrocodone approved
MDedge Hematology and Oncology